Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4
about
Interaction of human cytochrome P4503A4 with ritonavir analogsUpdate of KDBI: Kinetic Data of Bio-molecular Interaction database.Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycinComputational and in vitro studies on the inhibitory effects of herbal compounds on human cytochrome P450 1A2.The inhaled glucocorticoid fluticasone propionate efficiently inactivates cytochrome P450 3A5, a predominant lung P450 enzyme.The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis.Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin.Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets.The hungry stomach: physiology, disease, and drug development opportunities.Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.Pharmacogenetics/genomics and personalized medicine.Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants.Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.Grapefruit-drug interactions: can interactions with drugs be avoided?Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting.Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs.Inhibition of cytochromes p450: existing and new promising therapeutic targets.Application of mechanism-based CYP inhibition for predicting drug-drug interactions.Mechanisms of ketamine-involved regulation of cytochrome P450 gene expression.Herb-drug pharmacokinetic interactions reviewed.The role of diet on the clinical pharmacology of oral antineoplastic agents.How is sesamin metabolised in the human liver to show its biological effects?Drug-vitamin D interactions: a systematic review of the literatureNanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics.GSK962040: a small molecule motilin receptor agonist which increases gastrointestinal motility in conscious dogs.Analysis of Mechanism-Based Inhibition of CYP 3A4 by a Series of Fluoroquinolone Antibacterial Agents.Effects of liver fibrosis on verapamil pharmacokinetics in rats.Identification and analysis of the reactive metabolites related to the hepatotoxicity of safrole.In vitro-in vivo extrapolations to evaluate the effect of concomitant drugs on tacrolimus (FK506) exposure.Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy.Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes™ model.Pharmacokinetic consequences of time-dependent inhibition using the isolated perfused rat liver model.Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.Interindividual variability in dabigatran and rivaroxaban exposure: contribution ofABCB1genetic polymorphisms and interaction with clarithromycin
P2860
Q27678008-D9D320E0-9753-4657-8967-D6687ADE5940Q33381173-38464543-AB3B-428A-A33D-B6945CEC325EQ33613354-9FF709E1-B494-404B-B7ED-3810FF465989Q34039772-95598D61-990B-4981-8C13-67D459D425B1Q34076521-0AA8BA5B-B127-4FAE-A690-427B2D724AE1Q34357861-F2E69696-E394-4716-85B2-0AF3AC6CE109Q34589333-35DC7EE3-36C6-47B3-BB44-FAF5CA3B2A05Q34645793-842DB541-2240-439A-B348-84E746BB7DB7Q35015993-2DBA5B6C-6ABB-4FAB-AD56-A03514C257D9Q35065871-69022C77-D7C9-43FB-92E1-8D4C5C30CF01Q35215647-3B8DE600-8648-46FD-A8DF-AAB16C273333Q36072448-2E357336-3BD2-4CE5-A5B7-444322AD9A68Q36294685-5537F4C7-9095-4451-BCFE-1F5CF9A919A6Q36535990-7BC93AE3-3CC3-4D70-965C-2B19EF3E5112Q36558235-F70A5D69-9B13-4098-8B8D-D5C8DD6F15D2Q36652594-DE601102-1646-4361-8AE7-620ED3157D64Q36668891-F2A89929-3F1B-456F-AD6F-C57F2D455DBFQ36871056-CA10A785-0D5B-4151-B2F6-4915D0460E29Q36929602-8E12E539-94B2-4F77-A9DF-93C58E670AEBQ37494640-F3D16687-8FF2-470B-ACC9-AB4E1E93FDDEQ37693956-82FC179C-305C-459C-9487-D8F09B56426CQ37808478-2D92C51B-1B4C-4B0B-BF67-58B9274A5ABDQ37907103-033331F4-D5FE-4963-AF16-BAF80E843F12Q37958017-2D39087D-D17A-4283-963A-4B9211570EA8Q38073239-87A3110B-5D53-4CBA-85A5-1DDFBE528FE3Q38495022-011CBC6E-311F-4888-82F8-D8DBCE5B48A8Q43333422-52D85D24-D180-4F20-A8A7-5F776B714573Q46509647-3B036EA7-37D7-4332-8BDA-B14DD4A6AA1FQ46921383-356BB502-BEF6-468A-A465-7B4CA6A4F783Q47693100-BB3C4476-0826-4F89-B23D-FC937EBF4B60Q47760575-9B15EF30-8877-4110-82FE-1E4024DB185CQ48228997-82FF784F-8C67-4CD5-810F-ABD31E398872Q49345918-5A865AA7-9C25-4C44-A4F6-FFF267824D33Q51937078-45578A57-14D7-42A8-B194-58C8C954A385Q52334679-AB51A6A8-E8DF-40A4-ADFE-95F76EAA283FQ57314038-19A36413-DFF4-44FA-B68F-3AF954C3BB45
P2860
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4
@ast
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4
@en
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4
@nl
type
label
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4
@ast
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4
@en
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4
@nl
prefLabel
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4
@ast
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4
@en
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4
@nl
P2093
P356
P1476
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4
@en
P2093
Jiancheng Wang
Lee Yong Lim
Qiang Zhang
Shu Chuen Li
Shufeng Zhou
Urs A Boelsterli
P304
P356
10.2174/1389200043335450
P407
P577
2004-10-01T00:00:00Z